Digital Twins Key to Speedy Pharmaceutical Development
Summary
Labcorp is exploring AI-based digital biological twins that use medical data to model disease and simulate treatment scenarios. Researchers hope these models could help guide drug development, but they still need to prove that their predictions match real patient outcomes, and they do not replace clinical trials.Key Facts
- Labcorp performs more than 750 million diagnostic tests each year, according to its chief information and technology officer, Bola Oyegunwa.
- Labcorp aims to use diagnostic data, pathology records and medical images to build models of disease progression.
- The company’s longer-term goal is to use the models to simulate clinical trials.
- Some medical digital twins already model specific organs or diseases, including diseased hearts used to test procedures for dangerous irregular heart rhythms.
- Researchers have used computer-generated patients to help analyze clinical trial results and assess possible outcomes under different treatments.
- A virtual patient usually represents a hypothetical person based on population data, while a digital twin aims to represent a specific person or part of their biology using that person’s medical information.
- Inconsistent medical terminology and reporting can make health data difficult to combine and may affect AI model accuracy.
- Digital twins are not a substitute for clinical trials, and researchers still need to establish how accurately they predict patient outcomes.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.